Avadel Pharmaceuticals (STU:AWK) Total Liabilities : €82.35 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Total Liabilities?

Avadel Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €82.35 Mil.

Avadel Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (€87.10 Mil) to Dec. 2023 (€70.57 Mil) but then increased from Dec. 2023 (€70.57 Mil) to Mar. 2024 (€82.35 Mil).

Avadel Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€149.58 Mil) to Dec. 2022 (€145.31 Mil) and declined from Dec. 2022 (€145.31 Mil) to Dec. 2023 (€70.57 Mil).

Avadel Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Avadel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Total Liabilities Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

162.57

122.78

149.58

145.31

70.57

Avadel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															167.10	53.34	87.10	70.57	82.35

Avadel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avadel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	33.796	+	(1.55	+	35.225
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	70.57

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	151.028	-	80.457
	=	70.57

Avadel Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.983	+	(1.333	+	37.038
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	82.35

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	154.467	-	72.113
	=	82.35

Avadel Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (STU:AWK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.